Cinctive Capital Management LP Invests $659,000 in Moderna, Inc. (NASDAQ:MRNA)

Cinctive Capital Management LP acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 15,842 shares of the company's stock, valued at approximately $659,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. abrdn plc increased its position in Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock valued at $12,842,000 after acquiring an additional 69,360 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its position in Moderna by 30.9% during the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company's stock valued at $6,760,000 after purchasing an additional 23,881 shares in the last quarter. Spire Wealth Management boosted its holdings in shares of Moderna by 2,150.4% in the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company's stock valued at $966,000 after buying an additional 22,192 shares in the last quarter. Geode Capital Management LLC grew its holdings in Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after purchasing an additional 178,115 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its position in Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock valued at $6,127,000 after buying an additional 144,099 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MRNA. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday, March 21st. Morgan Stanley cut their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday. Finally, UBS Group lowered their price target on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of "Hold" and a consensus target price of $58.70.

Remove Ads

Moderna Trading Up 8.2 %

NASDAQ:MRNA traded up $2.03 during trading hours on Wednesday, hitting $26.67. The company had a trading volume of 13,082,139 shares, compared to its average volume of 7,113,632. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The company has a market cap of $10.31 billion, a P/E ratio of -2.87 and a beta of 2.23. The company has a 50-day moving average of $31.96 and a 200 day moving average of $41.54.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.